Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor

Cancer Research

Volumn 62, Issue 19, 2002, Pages 5611-5617

  Matsuda, Kei ^a   Idezawa, Takenao ^a   You, Xue Juan ^a   Kothari, Nayantara H ^a   Fan, Hung ^a   Korc, Murray ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOVIRUS VECTOR; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DIMERIZATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOGENESIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ADENOVIRIDAE; CELL DIVISION; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; GENETIC VECTORS; HUMANS; MAP KINASE SIGNALING SYSTEM; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0036792220     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA - Cancer J. Clin., 50: 7-33, 2000.
2. Korc, M. Role of growth factors in pancreatic cancer. Surg. Oncol. Clin. N. Am., 7: 25-41, 1998.
3. Hruban, R. H., Iacobuzio-Donahue, C., Wilentz, R. E., Goggins, M., and Kern, S. E. Molecular pathology of pancreatic cancer. Cancer J., 7: 251-258, 2001.
4. Hackel, P. O., Zwick, E., Prenzel, N., and Ullrich, A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol., 11: 184-189, 1999.
5. Bost, F., McKay, R., Bost, M., Potapova, O., Dean, N. M., and Mercola, D. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol. Cell. Biol., 19: 1938-1949, 1999.
6. Soltoff, S. P., Carraway, K. L., III, Prigent, S. A., Gullick, W. G., and Cantley, L. C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol., 14: 3550-3558, 1994.
7. Korc, M., Chandrasekar, B., Yamanaka, Y., Friess, H., Búchler, M. W., and Beget, H. G. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin. Investig., 90: 1352-1360, 1992.
8. Zhu, Z., Kleeff, J., Friess, H., Wang, L., Zimmermann, A., Yarden, Y., Búchler, M. W., and Korc, M. Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem. Biophys. Res. Commun., 273: 1019-1024, 2000.
9. Yamanaka, Y., Friess, H., Kobrin, M. S., Búchler, M. W., Beger, H. G., and Korc, M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res., 13: 565-569, 1993.
10. Wagner, M., Cao, T., Lopez, M. E., Hope, C., van Nostrand, K., Kobrin, M. S., Fan, H. U., Búchler, M. W., and Korc, M. Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Int. J. Cancer, 68: 782-787, 1996.
11. Overholser, J. P. Prewett, M. C., Hooper, A. T., Waksal, H. W., and Hicklin, D. J. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer (Phila.), 89: 74-82, 2000.
12. Bruns, C. J., Solorzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R., Fan, D., Abbruzzese, J., Traxler, P., Buchdunger, E., Radinsky, R., and Fidler, I. J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res., 60: 2926-2935, 2000.
13. Bruns, C. J., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R., McConkey, D. J., Evans, D. B., Abbruzzese, J. L., Hicklin, D. J., and Radinsky, R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res., 6: 1936-1948, 2000.
14. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36: 59-74, 1977.
15. Hoffman, P., and Carlin, C. Adenovirus E3 protein causes constitutively internalized epidermal growth factor receptors to accumulate in a prelysosomal compartment, resulting in enhanced degradation. Mol. Cell. Biol., 14: 3695-3706, 1994.
16. Baldwin, R. L., and Korc, M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor β-1. Growth Factors, 8: 23-34, 1993.
17. Kornmann, M., Arber, N., and Korc, M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin DI antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J. Clin. Investig., 101: 344-352, 1998.
18. Wagner, M., Lopez, M. E., Cahn, M., and Korc, M. Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo. Gastroenterology, 114: 798-807, 1998.
19. Waas, W. F., Lo, H. H., and Dalby, K. N. The kinetic mechanism of the dual phosphorylation of the ATF2 transcription factor by p38 mitogen-activated protein (MAP) kinase a. Implications for signal/response profiles of MAP kinase pathways. J. Biol. Chem., 276: 5676-5684, 2001.
20. Dickens, M., Rogers, J. S., Cavanagh, J., Raitano, A., Xia, Z., Halpern, J. R., Greenberg, M. E., Sawyers, C. L., and Davis, R. J. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science (Wash. DC), 277: 693-696, 1997.
21. Whitmarsh, A. J., and Davis, R. J. Analyzing JNK and p38 mitogen-activated protein kinase activity. Methods Enzymol. 332: 319-336, 2001.
22. Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S. S. Manning, A. M., and Anderson, D. W. SP600125. an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA, 98: 13681-13686, 2001.
23. Beerli, R. R., and Hynes, N. E. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J. Biol. Chem., 271: 6071-6076, 1996.
24. Tzahar, E., Pinkas Kramarski, R., Moyer, J. D., Klapper, L. N., Alroy, I., Levkowitz, G., Shelly, M., Henis, S., Eisenstein, M., Ratzkin, B. J., Sela, M., Andrews, G. C. and Yarden, Y. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J., 16: 4938-4950, 1997.
25. Kleeff, J., Ishiwata, T., Kumbasar, A., Friess, H., Búchler, M. W., Lander, A. D., and Korc, M. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J. Clin. Investig., 102: 1662-1673, 1998.
26. Gansauge, S., Gansauge, F., Ramadani, M., Stobbe, H., Rau, B., Harada, N., and Beger, H. G. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res., 57: 1634-1637, 1997.
27. Hsiang, D., Friess, H., Búchler, M. W., Ebert, M., Butler, J., and Korc, M. Absence of K-ras mutations in the pancreatic parenchyma of patients with chronic pancreatitis. Am. J. Surg., 174: 242-246, 1997.
28. Berrozpe, G., Schaeffer, J., Peinado, M. A., Real, F. X., and Perucho, M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int. J. Cancer, 58: 185-191, 1994.
29. Korc, M., Meltzer, P., and Trent, J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc. Natl. Acad. Sci. USA, 83: 5141-5144, 1986.
30. Riese, D. J., II, Komurasaki, T., Plowman, G. D., and Stem, D. F. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. J. Biol. Chem., 273: 11288-11294, 1998.
31. Alonso, G., Ambrosino, C., Jones, M., and Nebreda, A. R. Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength. J. Biol. Chem., 275: 40641-40648, 2000.
32. Maher, P. p38 mitogen-activated protein kinase activation is required for fibroblast growth factor-2-stimulated cell proliferation but not differentiation. J. Biol. Chem., 274: 17491-17498, 1999.
33. Rausch, O., and Marshall, C. J. Cooperation of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways during granulocyte colony-stimulating factor-induced hemopoietic cell proliferation. J. Biol. Chem., 274: 4096-4105, 1999.
34. Lavoie. J. N., Rivard, N., L'Allemain, G., and Pouyssegur, J. A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry. Prog. Cell Cycle Res., 2: 49-58, 1996.
35. 1-S through a mechanism requiring p38/RK. J. Biol. Chem., 272: 13229-13235, 1997.
36. Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., and Ullrich, A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature (Lond.), 402: 884-888, 1999.
37. Kanda, Y., Mizuno, K., Kuroki, Y., and Watanabe, Y. Thrombin-induced p38 mitogen-activated protein kinase activation is mediated by epidermal growth factor receptor transactivation pathway. Br. J. Pharmacol., 132: 1657-1664, 2001.
38. Kretzschmar, M., Doody, J., and Massagué, J. Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1. Nature (Lond.), 389: 618-622, 1997.
39. Baldwin, R. L., Friess, H., Yokoyama, M., Lopez, M. E., Kobrin, M. S., Búchler, M. W., and Korc, M. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int. J. Cancer, 67: 283-288, 1996.
40. Wagner, M., Kleeff, J., Lopez, M. E., Bockman, I., Massagué, J., and Korc, M. Transfection of the type I TGF-β receptor restores TGF-β responsiveness in pancreatic cancer. Int. J. Cancer, 78: 255-260, 1998.
41. Friess, H., Yamanaka, Y., Búchler, M. W., Ebert, M., Beger, H. G., Gold, L. I., and Korc, M. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology, 105: 1846-1856, 1993.
42. Kleeff, J., Maruyama, H., Ishiwata, T., Sawhney, H., Friess, H., Búchler, M. W., and Korc, M. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology, 116: 1202-1216. 1999.
43. Baker, C. H., Solorzano, C. C., and Fidler, I. J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res., 62: 1996-2003, 2002.
44. Yarden, Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer. 37 (Suppl. 4): 3-8, 2001.
45. Mendelsohn, J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer, 8: 3-9, 2001.